Remebot Neurosurgical Robot

The Remebot Neurosurgical Robot system represents China’s first domestically developed neurosurgical robot to receive NMPA approval, achieving market leadership with 52.6% share in 2023. Developed by Beijing Baihui Weikang Technology, the platform eliminates traditional stereotactic head frames while delivering 0.5mm positioning accuracy across nearly 100 surgical procedures.

Product Overview

The Remebot system integrates surgical planning software, optical tracking navigation, and a precision robotic arm into a unified platform for minimally invasive neurosurgery. Unlike frame-based stereotactic systems that require painful pin fixation to the skull, Remebot uses optical marker recognition for frameless registration, completing patient setup in under 2 minutes.

Eight product variants currently hold NMPA Class III medical device registration certificates, designed for different clinical settings and procedure types. The flagship models serve major tertiary hospitals for complex DBS and tumor procedures, while dedicated hemorrhagic stroke variants enable deployment to county-level facilities for emergency neurosurgery.

Key Features

Approved in China since April 2018, the Remebot Neurosurgical Robot holds 52.6% domestic market share and supports nearly 100 procedures across 12 categories, from DBS to hematoma aspiration.

• Frameless Stereotactic Navigation: Optical tracking system recognizes customized markers without requiring invasive head frame fixation, reducing patient discomfort and setup time

• Multi-Modal Image Fusion: Integrates CT, MRI, PET, and DTI imaging data for thorough surgical planning and target visualization

• Real-Time Motion Compensation: Visible-light tracking at high frequency enables continuous patient position monitoring, automatically adjusting for movement during procedures

• Force-Sensing Control: Integrated force sensors provide haptic feedback and safety limits during instrument manipulation

• Fully Localized Components: Proprietary optical tracking system and surgical robotic arm eliminate dependence on imported components

Technical Specifications

Approved since April 2018, the Remebot system achieves ≤0.5 mm positioning with sub-2-minute frameless registration across CT, MRI, PET, and DTI imaging modalities via 6-DOF optical tracking.

Product Variants

Clinical Applications

The Remebot platform supports procedures across 12 major categories:

Functional Neurosurgery

• Deep brain stimulation (DBS) for Parkinson’s disease and essential tremor
• Epilepsy surgery including SEEG electrode placement
• Ablative procedures for movement disorders

Cerebrovascular

• Intracerebral hematoma aspiration for hemorrhagic stroke
• Stereotactic aspiration of brain abscesses

Neuro-oncology

• Stereotactic biopsy of intracranial tumors
• Craniotomy navigation for tumor resection
• Brachytherapy seed implantation

Other Applications

• Endoscopic neurosurgery navigation
• Ventricular catheter placement
• Foreign body localization and removal

Clinical Evidence

As of 2024, the Remebot neurosurgical robot has supported over 40,000 clinical procedures across more than 400 hospitals in China. In 2023 alone, more than 8,000 surgeries were performed using the system.

A 2019 study published in the International Journal of Medical Robotics documented the treatment of 17 patients with hypertensive intracerebral hemorrhage using the Remebot system, demonstrating the platform’s efficacy in emergency neurosurgical applications.

The system completed China’s first 5G remote DBS surgery in November 2021, with Beijing Tiantan Hospital guiding a procedure at Zhangjiakou First Hospital, demonstrating telesurgery capabilities.

Regulatory Status

Market Position

According to Frost & Sullivan’s 2024 report, Remebot achieved 40 unit orders in 2023, representing 52.6% market share in China’s neurosurgical robot segment. Combined with Huake Precision, domestic manufacturers hold over 80% of the market, with imported systems (primarily Zimmer Biomet) accounting for less than 2%.

The platform’s pricing advantage from localized components has enabled penetration into previously underserved regions including Guizhou, Qinghai, Chongqing Dianjiang, Inner Mongolia, and Xinjiang.

Frequently Asked Questions

What procedures can the Remebot neurosurgical robot perform?

The system supports nearly 100 procedures across 12 categories, including deep brain stimulation, stereotactic biopsy, hematoma aspiration, endoscopic navigation, and craniotomy guidance. It is particularly established for DBS surgery, being China’s first domestically developed robot to perform this procedure.

How does Remebot compare to the ROSA Brain system?

Both are frameless stereotactic neurosurgical robots. Remebot uses visible-light optical tracking versus ROSA’s laser-based approach, enabling faster registration (under 2 minutes). Remebot’s fully localized components result in significantly lower acquisition and maintenance costs, making it accessible to primary care facilities in China.

What is the positioning accuracy?

The system achieves positioning accuracy within 0.5mm, comparable to international alternatives. Clinical studies have validated this precision across thousands of procedures.

Is the Remebot available outside China?

International deployment began in March 2024 with installation in Kazakhstan, completing that country’s first robot-assisted neurosurgical procedure. The company has since expanded into Central Asia, Southeast Asia, and South America.